Abstract
Cystic fibrosis is the first genetic disorder for which universal screening of preconceptional or prenatal patients became a component of standard prenatal care. The molecular genetics and mutation profile of the CFTR gene are complex, with a wide range of phenotypic consequences. Carrier screening can facilitate risk assessment for prospective parents to have an affected offspring, although there remains a small residual risk for carrying a mutation even with a negative screening result. There are ethnic differences with respect to disease incidence and effectiveness of carrier testing, which may complicate counseling.
Original language | English (US) |
---|---|
Pages (from-to) | 47-59 |
Number of pages | 13 |
Journal | Obstetrics and Gynecology Clinics of North America |
Volume | 37 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2010 |
Keywords
- CFTR
- Carrier testing
- Cystic fibrosis
- Mutation panel
ASJC Scopus subject areas
- Obstetrics and Gynecology